

"Express Mail" mailing label number EL 315 815 305 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 11-16-99

By: Nancy Ramos
Printed: Nancy Ramos

jc503 U.S. PTO
09/441723
11/16/99



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No. 08/978,174, filed on November 25, 1997, entitled NEW GLUTATHIONE S-TRANSFERASE.

1. Enclosed is a copy of the prior application, U.S. Application Serial No. 08/978,174 filed November 25, 1997, including the oath or declaration as originally signed.
2. With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the computer readable form of the "Sequence Listing" for the instant divisional application is identical with that filed for Serial No. 08/978,174, filed November 25, 1997, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 08/978,174 as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3. Cancel in this application original claims 3-13, 20 and 21 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
4. The inventors of the invention being claimed in this application are: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah.

5. In accordance with 37 CFR 1.63(d), a copy of the originally signed declaration showing applicants' signatures as filed on March 10, 1998 is enclosed.
6. Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number 08/978,174, filed November 25, 1997."
7. The filing fee is calculated below:

| Claims | Number Filed | Minus | Number Extra | Other Than Small Entity Rate | Fee | Basic Fee |
|--|--------------|-------|--------------|------------------------------|---------------|-----------|
| Total Claims | 10 | -20 | 0 | x \$18 | | \$0 |
| Indep. Claims | 1 | -3 | 0 | x \$78 | | \$0 |
| <u>Multiple Dependent Claim(s), if any</u> | | | | | <u>+\$260</u> | \$0 |

TOTAL FILING FEE \$ 760.00

8. An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
9. Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108 in the amount of \$760.00.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Incyte Pharmaceuticals, Inc. Account No. 09-0108.

Duplicate copies of these papers are enclosed.

10. New formal drawings are enclosed.
11. The prior application is assigned of record to Incyte Pharmaceuticals, Inc, recorded on March 16, 1998, at reel 9094/frame 0979.
12. A preliminary amendment is enclosed.
13. Also enclosed Return Postcard, Information Disclosure Statement, List of Cited References (1449), and copy of previously submitted Certificate, Revocation of Power of Attorney and Appointment of New Attorneys.

14. X The power of attorney of the prior application is to:

| | |
|------------------------|-----------------|
| Narinder S. Banait | Reg. No. 43,482 |
| Adam Warwick Bell | Reg. No. 43,490 |
| Lucy J. Billings | Reg. No. 36,749 |
| Michael C. Cerrone | Reg. No. 39,132 |
| Diana Hamlet-Cox | Reg. No. 33,302 |
| Colette C. Muenzen | Reg. No. 39,784 |
| Lynn E. Murry | Reg. No. 42,918 |
| Danielle M. Pasqualone | Reg. No. 43,847 |
| Susan K. Sather | Reg. No. 44,316 |
| David G. Streeter | Reg. No. 43,168 |

- a. An associate power of attorney is attached.
- b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

INCYTE PHARMACEUTICALS, INC.
 PATENT DEPARTMENT
 3174 Porter Drive
 Palo Alto, California 94304
 Phone: (650) 855-0555, Fax: (650) 849-8886

Date: November 14, 1991 By: David G. Streeter
 David G. Streeter, Ph. D.
 Reg. No. 43,168
 Direct Dial Telephone: (650) 845-5741

- Inventor(s)
- Assignee of complete interest
- X Attorney or agent of record
- Filed under 37 CFR 1.34(a)
- Registration number if acting under 37 CFR 1.34(a) _____.

"Express Mail" mailing label number EL 315 815 305 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 11-16-89

By: Nancy Ramos
Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: NEW GLUTATHIONE S-TRANSFERASE

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows:

IN THE SPECIFICATION

Please amend the specification as follows:

At page 13, delete lines 8-11.

At page 14, line 16, delete "Fig. 1" and insert --Figures 1A, 1B, and 1C--.

At page 28, line 30, delete "immunoglobin" and insert --immunoglobulin--.

At page 33, line 19, delete "Hanks's" and insert --Hanks'--.

At page 36, line 5, delete "formation The" and insert --formation. The--.

At page 36, line 6, delete "," after photometric.

At page 36, line 7, delete "subject, control and disease, samples" and insert --subject samples, control and disease--.

IN THE CLAIMS

Please cancel claims 3-13, 20 and 21 without prejudice.

Please amend claim 1 as follows.

1. (Once Amended) A substantially purified new glutathione S-transferase (GSTS) comprising the amino acid sequence of SEQ ID NO:1, or a catalytic or immunogenic fragment of SEQ ID NO:1.

Please add new claims 22 -25 as follows.

22. (New) A method of producing an antibody using the protein of claim 1, comprising;

- a) immunizing an animal with the protein or an antigenically-effective fragment thereof, under conditions whereby an antibody response is elicited; and
- b) isolating from the immunized animal antibodies that specifically bind to the protein.

23. (New) A method for using a protein to screen a large number of molecules or compounds, the method comprising:

- (a) combining the protein of claim 1 with the compound or molecule under conditions to allow complex formation; and
- (b) detecting complex formation, wherein the presence of the complex identifies a molecule that specifically binds the protein.

24. (New) The method of claim 23 wherein the molecules and compounds are selected from DNA molecules, RNA molecules, peptide nucleic acids, agonists, antagonists, antibodies, immunoglobulins, pharmaceutical agents, and drug compounds.

25. (New) A method of using a protein or a fragment thereof to purify a molecule or compound which specifically binds the protein from a sample, the method comprising:

- a) combining the protein or a fragment thereof of claim 1 with a sample under

conditions to allow specific binding;

- b) recovering the bound protein; and
- d) separating the protein from the molecule or compound, thereby obtaining purified molecule or compound.


REMARKS

Justification for the amendments is as follows. The above amendments correct inadvertent typographical and grammatical errors in the specification. Support for the amendment to claim 1 is found, for example, at page 42, lines 17-22 and for new claim 22 at page 27, line 26 through page 29, line 15. Support for new claims 23-24 is found, for example, at page 11, lines 24-29 (peptide nucleic acids), at page 17, lines 20-25 (nucleic acids), at page 18, lines 26-30 (peptides), at page 26, lines 2-20 (antibodies, immunoglobulins), at page 27, lines 23-25 (pharmaceutical agents), at page 32, lines 5-6 (mimetics, agonists, antagonists, inhibitors), at page 43, lines 2-5 (drug compounds), and at page 52, lines 2-7 (binding assays). Support for new claim 25 is found at page 12, lines 10-16 and at page 13, lines 4-7. No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: November 16, 1991



David G. Streeter, Ph. D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

New Glutathione S-Transferase

FIELD OF THE INVENTION

This invention relates to nucleic acid and amino acid sequences of a new glutathione S-transferase and to the use of these sequences in the diagnosis, prevention, and treatment of diseases associated with cell proliferation.

5

BACKGROUND OF THE INVENTION

The glutathione S-transferases (GST) are a ubiquitous family of enzymes with dual substrate specificities that perform important biochemical functions including xenobiotic biotransformation and detoxification, drug metabolism, and protection of tissues against peroxidative damage and subsequent inflammatory responses. The basic reaction catalyzed by these enzymes is the conjugation of an electrophilic substrate with reduced glutathione (GSH), which results in either activation or deactivation/detoxification of the substrate. The requirement for conjugating reduced GSH to a wide variety of substrates necessitates a diversity in GST structures in various organisms and cell types.

GSTs are homodimeric or heterodimeric proteins localized in the cell cytosol. The major isozymes share common structural and catalytic properties, and in man have been classified into four major classes, Alpha, Mu, Pi, and Theta. The two largest classes, Alpha and Mu, are identified by their respective protein isoelectric points: pI ~ 7.5-9.0 (Alpha) and pI ~ 6.6 (Mu). Each GST possesses a common binding site for GSH and a variable hydrophobic binding site. The hydrophobic binding site in each isozyme is specific for particular electrophilic substrates.

In most cases, GSTs perform the beneficial function of deactivating and detoxifying potentially mutagenic and carcinogenic chemicals. However, in some cases their action is detrimental and produces mutagenic and carcinogenic compounds. Some forms of rat and human GSTs are thus reliable preneoplastic markers. Expression of human GSTs in bacterial strains, such as Salmonella typhimurium, used in the well known Ames test for mutagenicity, has helped to establish the role of these enzymes in mutagenesis. Studies have

shown that dihalomethanes are more mutagenic in bacterial cells which express human GST than in cells which do not express GST (Thier, R. et al. (1993) Proc. Natl. Acad. Sci. 90: 8576-8580). The mutagenicity of ethylene dibromide and ethylene dichloride is increased in bacterial cells expressing the human Alpha GST, A1-1, while the mutagenicity of aflatoxin B1 is substantially reduced by enhancing the expression of GST (Simula, T.P. et al. (1993) Carcinogenesis 14:1371-6).

5 GST has been implicated in the acquired resistance of many cancers to drug treatment. Multi-drug resistance occurs when cancer cells are treated with and subsequently become 10 resistant to cytotoxic drugs. Elevated GST levels are observed in some drug resistant cancers. It is believed that the drug being used to treat the cancer is deactivated by the GST-catalyzed 15 GSH conjugation reaction. The increased GST levels protect the cancer cells from all cytotoxic agents for which that GST has affinity. Increased levels of A1-1 in tumors has been linked to drug resistance induced by cyclophosphamide treatment (Dirven H.A. et al. (1994) Cancer Res. 54: 6215-20).

15 The most abundant mammalian GSTs are the class alpha, mu, and pi enzymes. The biological control of these families is complex and exhibits sex-, age-, tissue-, species-, and tumor-specific patterns of expression. In addition, GSTs are regulated by a structurally 20 diverse range of xenobiotics, and at least 100 chemicals have been identified that induce GST. A significant number of these chemical inducers occur naturally and, as they are found as nonnutrient components in vegetables and citrus fruits, it is apparent that humans are likely to be regularly exposed to such compounds. Class alpha, mu, and pi GST isoenzymes are overexpressed in rat hepatic preneoplastic nodules and the increased levels of these enzymes are believed to contribute to the multi-drug resistant phenotype observed in these lesions. The 25 majority of human tumors and human tumors cell lines express significant amounts of class pi GST. Cell lines selected in-vitro for resistance to anticancer drugs frequently overexpress class pi GST, although overexpression of the class alpha and mu isoenzymes is also often observed.

30 The discovery of a new human glutathione S-transferase and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of diseases associated with cell proliferation, in

particular, cancers and immune disorders.

SUMMARY OF THE INVENTION

The invention features a substantially purified polypeptide, new glutathione S-transferase (GSTS), comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

The invention further provides a substantially purified variant of GSTS having at least 90% amino acid identity to the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also provides an isolated and purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

Additionally, the invention provides a composition comprising a polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention further provides an isolated and purified polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, as well as an isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

The invention also provides an isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or a fragment of SEQ ID NO:2, and an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide comprising SEQ ID NO:2 or a fragment of SEQ ID NO:2. The invention also provides an isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence comprising SEQ ID NO:2 or a fragment of SEQ ID NO:2.

The invention further provides an expression vector containing at least a fragment of the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of

SEQ ID NO:1 or a fragment of SEQ ID NO:1. In another aspect, the expression vector containing the polynucleotide sequence is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide sequence encoding GSTS under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified GSTS having the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, as well as a purified agonist and a purified antagonist of the polypeptide.

The invention also provides a method for treating or preventing an immune response, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist to GSTS.

The invention also provides a method for treating or preventing a cancer, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist to GSTS.

The invention also provides a method for detecting a polynucleotide encoding GSTS in a biological sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence encoding the polypeptide comprising SEQ ID NO:1 or a fragment of SEQ ID NO:1 to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding GSTS in the biological sample. In one aspect, the nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to the hybridizing step.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A, 1B, and 1C show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of GSTS. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co. Ltd. San Bruno, CA).

5 Figure 2 shows the amino acid sequence alignments among GSTS (SEQ ID NO:1), and rat glutathione S-transferase subunit 13 (rGST) (GI 1911748; SEQ ID NO:3) produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

10 Figures 3A and 3B show the hydrophobicity plots for GSTS, SEQ ID NO: 1 and rGST (SEQ ID NO:3), respectively ; the positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity (MacDNASIS PRO software).

DESCRIPTION OF THE INVENTION

15 Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

20 It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a host cell” includes a plurality of such host cells, reference to the “antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

25 Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and

methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

5 **DEFINITIONS**

GSTS, as used herein, refers to the amino acid sequences of substantially purified GSTS obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

10 The term "agonist", as used herein, refers to a molecule which, when bound to GSTS, increases or prolongs the duration of the effect of GSTS. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of GSTS.

15 An "allele" or "allelic sequence", as used herein, is an alternative form of the gene encoding GSTS. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes 20 may occur alone, or in combination with the others, one or more times in a given sequence.

25 "Altered" nucleic acid sequences encoding GSTS as used herein include those with deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent GSTS. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GSTS, and improper or unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GSTS. The encoded protein may also be "altered" and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GSTS. Deliberate amino acid substitutions may be made on the 30 basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the

amphipathic nature of the residues as long as the biological or immunological activity of GSTS is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may 5 include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and threonine, and phenylalanine and tyrosine.

“Amino acid sequence” as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragment thereof, and to naturally occurring or synthetic molecules. Fragments of GSTS are preferably about 5 to about 15 amino acids in length and retain the 10 biological activity or the immunological activity of GSTS. Where “amino acid sequence” is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, amino acid sequence, and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

“Amplification” as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term “antagonist” as used herein, refers to a molecule which, when bound to GSTS, decreases the amount or the duration of the effect of the biological or immunological 20 activity of GSTS. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules which decrease the effect of GSTS.

As used herein, the term “antibody” refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind GSTS polypeptides can be prepared using intact polypeptides or 25 fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal can be derived from the translation of RNA or synthesized chemically and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin, keyhole limpet hemocyanin. The coupled peptide is then used to immunize 30 the animal (e.g., a mouse, a rat, or a rabbit).

The term "antigenic determinant", as used herein, refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense", as used herein, refers to any composition containing nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules include peptide nucleic acids and may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and block either transcription or translation. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic GSTS, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands and in the design and use of PNA molecules.

A "composition comprising a given polynucleotide sequence" as used herein refers broadly to any composition containing the given polynucleotide sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GSTS (SEQ ID NO:1) or fragments thereof (e.g., SEQ ID NO:2 and fragments thereof) may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS) and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus", as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly (e.g., GELVIEW™ Fragment Assembly system, GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding GSTS in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

A "deletion", as used herein, refers to a change in the amino acid or nucleotide sequence and results in the absence of one or more amino acid residues or nucleotides.

The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding or complementary to GSTS or the encoded GSTS. Such modifications include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative encodes a polypeptide which retains the biological or immunological function of the natural molecule. A derivative polypeptide is one which is modified by glycosylation, pegylation, or any similar process which retains the biological or immunological function of the polypeptide from which it was derived.

The term "homology", as used herein, refers to a degree of complementarity. There

may be partial homology or complete homology (i.e., identity). A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence

- 5 may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low
10 stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity). In the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

15 Human artificial chromosomes (HACs) are linear microchromosomes which may contain DNA sequences of 10K to 10M in size and contain all of the elements required for stable mitotic chromosome segregation and maintenance (Harrington, J.J. et al. (1997) Nat Genet. 15:345-355).

20 The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

The term "hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

25 The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or between one nucleic acid
30 sequence present in solution and another nucleic acid sequence immobilized on a solid

support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or 5 nucleotides, respectively, as compared to the naturally occurring molecule.

"Microarray" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The term "modulate", as used herein, refers to a change in the activity of GSTS. For 10 example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional or immunological properties of GSTS.

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand.

"Fragments" are those nucleic acid sequences which are greater than 60 nucleotides than in 15 length, and most preferably includes fragments that are at least 100 nucleotides or at least 1000 nucleotides, and at least 10,000 nucleotides in length.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 20 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20 to 25 nucleotides, which can be used in PCR amplification or a hybridization assay, or a microarray. As used herein, oligonucleotide is substantially equivalent to the terms "amplimers", "primers", "oligomers", and "probes", as commonly defined in the art.

"Peptide nucleic acid", PNA as used herein, refers to an antisense molecule or 25 anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues which ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in the cell where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

30 The term "portion", as used herein, with regard to a protein (as in "a portion of a given

protein") refers to fragments of that protein. The fragments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length GSTS and fragments thereof.

5 The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding GSTS, or fragments thereof, or GSTS itself may comprise a bodily fluid, extract from a cell, chromosome, organelle, or membrane isolated from a cell, a cell, genomic DNA, RNA, or cDNA(in solution or bound to a solid support, a tissue, a tissue print, and the like.

10 The terms "specific binding" or "specifically binding", as used herein, refers to that interaction between a protein or peptide and an agonist, an antibody and an antagonist. The interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) of the protein recognized by the binding molecule. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

15 As used herein, the term "stringent conditions" refers to conditions which permit hybridization between polynucleotide sequences and the claimed polynucleotide sequences. Suitably stringent conditions can be defined by, for example, the concentrations of salt or
20 formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

25 For example, hybridization under high stringency conditions could occur in about 50% formamide at about 37°C to 42°C. Hybridization could occur under reduced stringency conditions in about 35% to 25% formamide at about 30°C to 35°C. In particular, hybridization could occur under high stringency conditions at 42°C in 50% formamide, 5X SSPE, 0.3% SDS, and 200 µg/ml sheared and denatured salmon sperm DNA. Hybridization could occur under reduced stringency conditions as described above, but in 35% formamide
30 or at a reduced temperature of 35°C. The temperature range corresponding to a particular

level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.

The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

A "variant" of GSTS, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or

immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

THE INVENTION

5 The invention is based on the discovery of a new human new glutathione S-transferase (hereinafter referred to as "GSTS"), the polynucleotides encoding GSTS, and the use of these compositions for the diagnosis, prevention, or treatment of cancer and immune response.

Nucleic acids encoding the GSTS of the present invention were first identified in
10 Incyte Clone 1554593 from the urologic cDNA library (BLADTUT04) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 1554593 (BLADTUT04), 700343 (SYNORAT03), 1597768 (BRAINOT14), and 140829 (TLYMNOR01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Fig. 1. GSTS is 226 amino acids in length and has one potential casein kinase II phosphorylation site at residue S¹²⁷; one potential microbodies c-terminal targeting signal at residue A²²⁴; two potential protein kinase C phosphorylation site at residues T¹⁶¹ and S²⁰⁰; and one potential tyrosine kinase phosphorylation site at residue R⁶. As shown in Fig. 2, GSTS has chemical and structural homology with rGST (GI 1911749; SEQ ID NO:3) etc. In particular, GSTS and rGST share 70% identity, the microbodies C-terminal targeting signal at residue A²²⁴, and the protein kinase C phosphorylation site at residue S²⁰⁰. As illustrated by Figs. 3A and 3B, GSTS and rGST have rather similar hydrophobicity plots. Northern analysis shows the expression of
20 this sequence in various libraries, at least 49% of which are immortalized or cancerous and at least 27% of which involve immune response.

The invention also encompasses GSTS variants. A preferred GSTS variant is one having at least 80%, and more preferably at least 90%, amino acid sequence identity to the GSTS amino acid sequence (SEQ ID NO:1) and which retains at least one biological, immunological or other functional characteristic or activity of GSTS. A most preferred
30

GSTS variant is one having at least 95% amino acid sequence identity to SEQ ID NO:1.

The invention also encompasses polynucleotides which encode GSTS. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of GSTS can be used to produce recombinant molecules which express GSTS. In a particular embodiment, the 5 invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NO:2 as shown in Fig. 1A, 1B, and 1C.

The invention also encompasses a variant of a polynucleotide sequence encoding GSTS. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide 10 sequence identity to the polynucleotide sequence encoding GSTS. A particular aspect of the invention encompasses a variant of SEQ ID NO:2 which has about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to SEQ ID NO:2.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding GSTS, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide 15 sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring GSTS, and all such variations are to be 20 considered as being specifically disclosed.

Although nucleotide sequences which encode GSTS and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring GSTS under 25 appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GSTS or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which 30 particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GSTS and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties,

such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or fragments thereof, which encode GSTS and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and 5 cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GSTS or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency as taught in Wahl, G.M. and S.L. Berger (1987; 10 Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

Methods for DNA sequencing which are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 15 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ 20 Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

The nucleic acid sequences encoding GSTS may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may 25 be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the 30 first one. Products of each round of PCR are transcribed with an appropriate RNA

polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may be designed using commercially available software such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light

intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which 5 might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GSTS may be used in recombinant DNA molecules to direct expression of GSTS, fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially 10 the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express GSTS.

As will be understood by those of skill in the art, it may be advantageous to produce GSTS-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable 15 properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GSTS encoding sequences for a variety of reasons, 20 including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new 25 restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GSTS may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of GSTS activity, it may be 30 useful to encode a chimeric GSTS protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between

the GSTS encoding sequence and the heterologous protein sequence, so that GSTS may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding GSTS may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of GSTS, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of GSTS, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active GSTS, the nucleotide sequences encoding GSTS or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GSTS and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express

sequences encoding GSTS. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

The “control elements” or “regulatory sequences” are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding GSTS, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for GSTS. For example, when large quantities of GSTS are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding GSTS may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem.

264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

5 In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For 10 reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding GSTS may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in 20 McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

An insect system may also be used to express GSTS. For example, in one such 25 system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding GSTS may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of GSTS will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells 30 or Trichoplusia larvae in which GSTS may be expressed (Engelhard, E.K. et al. (1994) Proc.

Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GSTS may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing GSTS in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6 to 10M are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GSTS. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding GSTS, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding

and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; Bethesda, MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express GSTS may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector.

Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines.

These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or aprt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*).

Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable

protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, 5 if the sequence encoding GSTS is inserted within a marker gene sequence, transformed cells containing sequences encoding GSTS can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GSTS under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

10 Alternatively, host cells which contain the nucleic acid sequence encoding GSTS and express GSTS may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

15 The presence of polynucleotide sequences encoding GSTS can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding GSTS. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding GSTS to detect transformants containing DNA or RNA encoding GSTS.

20 A variety of protocols for detecting and measuring the expression of GSTS, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GSTS is 25 preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

30 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing

labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GSTS include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GSTS, or any fragments thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are 5 known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used for ease of 10 detection, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GSTS may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GSTS may be designed to contain signal sequences which direct secretion of GSTS through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding GSTS to nucleotide sequence encoding a polypeptide domain which will facilitate 15 purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity 20 purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and GSTS may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing GSTS and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMAC (immobilized metal ion affinity 25 chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while the

enterokinase cleavage site provides a means for purifying GSTS from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of GSTS may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of GSTS may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

THERAPEUTICS

Chemical and structural homology exists between/among GSTS and rGST from rat (GI1911741). Northern analysis shows that the expression of GSTS is associated with cell proliferation, cancer, and immune disorders.

Therefore, in one embodiment, an antagonist of GSTS may be administered to a subject to prevent or treat an immune disorder. Immune disorders may include, but are not limited to AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and 25 autoimmune thyroiditis; complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. In one aspect, an antibody which specifically binds GSTS may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GSTS.

30 In another embodiment, a vector expressing the complement of the polynucleotide

encoding GSTS may be administered to a subject to treat or prevent an immune disorder including, but not limited to, the disorders described above.

In another embodiment, an antagonist of GSTS or a fragment or derivative thereof may be administered to a subject to treat or prevent a cancer. Such cancers include, but are 5 not limited to, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma; and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. In one aspect, an antibody which specifically binds GSTS may 10 be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GSTS.

In another embodiment, a vector capable of expressing the complement of the polynucleotide encoding GSTS may be administered to a subject to treat or prevent a cancer including, but not limited to, those cancers listed above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. 20 Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GSTS may be produced using methods which are generally known in the art. In particular, purified GSTS may be used to produce antibodies or to screen 25 libraries of pharmaceutical agents to identify those which specifically bind GSTS.

Antibodies to GSTS may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic 30 use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with GSTS or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, 5 but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies 10 to GSTS have an amino acid sequence consisting of at least five amino acids and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of GSTS amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to GSTS may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. 25 (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; Takeda, S. et al. (1985) *Nature* 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GSTS-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from 30 random combinatorial immunoglobulin libraries (Burton D.R. (1991) *Proc. Natl. Acad. Sci.*

88:11120-3).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 5 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for GSTS may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments.

10 Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

15 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GSTS and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GSTS epitopes is preferred, but a competitive binding assay may also be employed (Maddox, *supra*).

20 In another embodiment of the invention, the polynucleotides encoding GSTS, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding GSTS may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding GSTS. Thus, 25 complementary molecules or fragments may be used to modulate GSTS activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding GSTS.

30 Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the

targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence which is complementary to the polynucleotides of the gene encoding GSTS. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

5 Genes encoding GSTS can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes GSTS. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases.

10 Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions of the gene encoding GSTS (signal sequence, promoters, enhancers, and introns). Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

25 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GSTS.

30 Specific ribozyme cleavage sites within any potential RNA target are initially

identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the 5 oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These 10 include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GSTS. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in 20 the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally 25 suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections or polycationic amino polymers (Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-66; incorporated herein by reference) may be achieved using methods which are well known in the art.

30 Any of the therapeutic methods described above may be applied to any subject in need

of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for 5 any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of GSTS, antibodies to GSTS, mimetics, agonists, antagonists, or inhibitors of GSTS. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and 10 water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, 15 intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be 20 found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as 25 tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain 30 tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars,

including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the 5 cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents 10 or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's 20 solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as 25 ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to 30 be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

5 The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, 10 and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of GSTS, such labeling would include amount, frequency, and method of administration.

15 Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

20 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

25 A therapeutically effective dose refers to that amount of active ingredient, for example GSTS or fragments thereof, antibodies of GSTS, agonists, antagonists or inhibitors of GSTS, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical 30 compositions which exhibit large therapeutic indices are preferred. The data obtained from

cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of 5 administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, 10 weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

20

DIAGNOSTICS

In another embodiment, antibodies which specifically bind GSTS may be used for the diagnosis of conditions or diseases characterized by expression of GSTS, or in assays to monitor patients being treated with GSTS, agonists, antagonists or inhibitors. The antibodies 25 useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for GSTS include methods which utilize the antibody and a label to detect GSTS in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules 30 which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring GSTS are known in the art and provide a basis for diagnosing altered or abnormal levels of GSTS expression. Normal or standard values for GSTS expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to GSTS under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of GSTS expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GSTS may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of GSTS may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of GSTS, and to monitor regulation of GSTS levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GSTS or closely related molecules, may be used to identify nucleic acid sequences which encode GSTS. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding GSTS, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the GSTS encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring GSTS.

Means for producing specific hybridization probes for DNAs encoding GSTS include

the cloning of nucleic acid sequences encoding GSTS or GSTS derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes 5 may be labeled by a variety of reporter groups, for example, radionuclides such as 32P or 35S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GSTS may be used for the diagnosis of conditions or disorders which are associated with expression of GSTS.

10 Examples of such conditions or disorders include cancers such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma; and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and immune 15 disorders such as AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or 20 pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma.

25 The polynucleotide sequences encoding GSTS may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dipstick, pin, ELISA assays or microarrays utilizing fluids or tissues from patient biopsies to detect altered GSTS expression. Such qualitative or quantitative methods are well known in the art.

30 In a particular aspect, the nucleotide sequences encoding GSTS may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding GSTS may be labeled by standard methods, and

added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample,

5 the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding GSTS in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

10 In order to provide a basis for the diagnosis of disease associated with expression of GSTS, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes GSTS, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the 15 values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

20 Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

25 With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the 30 development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding GSTS may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'->3') and another with antisense (3'<-5'), 5 employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of GSTS include 10 radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) *J. Immunol. Methods*, 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and 15 a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, an oligonucleotide derived from any of the polynucleotide sequences described herein may be used as a target in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously (to produce a transcript image), and to identify genetic variants, mutations and polymorphisms. This 20 information will be useful in determining gene function, understanding the genetic basis of disease, diagnosing disease, and in developing and monitoring the activity of therapeutic agents (Heller, R. et al. (1997) *Proc. Natl. Acad. Sci.* 94:2150-55).

In one embodiment, the microarray is prepared and used according to the methods described in PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; *Nat. 25 Biotech.* 14: 1675-1680) and Schena, M. et al. (1996; *Proc. Natl. Acad. Sci.* 93: 10614-10619), all of which are incorporated herein in their entirety by reference.

The microarray is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides 30 in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25

nucleotides in length. For a certain type of microarray, it may be preferable to use oligonucleotides which are only 7-10 nucleotides in length. The microarray may contain oligonucleotides which cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray may be oligonucleotides that are specific to a gene or genes of interest in which at least a fragment of the sequence is known or that are specific to one or more unidentified cDNAs which are common to a particular cell type, developmental or disease state.

In order to produce oligonucleotides to a known sequence for a microarray, the gene of interest is examined using a computer algorithm which starts at the 5' or more preferably at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray. The "pairs" will be identical, except for one nucleotide which preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and one million which lends itself to the

efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray so that the probe sequences hybridize to complementary oligonucleotides of the microarray. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies on the sequences, mutations, variants, or polymorphisms among samples.

In another embodiment of the invention, the nucleic acid sequences which encode GSTS may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome or to artificial chromosome constructions, such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) Blood Rev. 7:127-134, and Trask, B.J. (1991) Trends Genet. 7:149-154.

Fluorescent in situ hybridization (FISH as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in various scientific journals or at Online Mendelian Inheritance in Man (OMIM). Correlation between the location of the gene encoding GSTS on a physical chromosomal map and a specific disease , or predisposition to a

specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, GSTS, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between GSTS and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to GSTS large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with GSTS, or fragments thereof, and washed. Bound GSTS is then detected by methods well known in the art. Purified GSTS can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the

peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GSTS specifically compete with a test compound for binding GSTS. In this manner, the antibodies can be used to detect the presence of any 5 peptide which shares one or more antigenic determinants with GSTS.

In additional embodiments, the nucleotide sequences which encode GSTS may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

10 The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

I BLADTUT04 cDNA Library Construction

The BLADTUT04 cDNA library was constructed from associated cancerous bladder tissue from the same donor. Both tissues were obtained from a 60-year-old Caucasian male following excision during a radical cystectomy of a grade 3 transitional cell carcinoma in the left bladder wall which extended through the muscularis propria into the perivascular fat. Carcinoma in-situ was identified in the dome and trigone. The distal urethral margin was 15 negative for tumor, but the prostate showed adenofibromatous hyperplasia. The patient presented with dysuria and slowing of the urinary stream. In addition to the cystectomy, the patient underwent a prostatectomy and vasectomy. Family history included diabetes, type I, in both the mother and father, a malignant neoplasm of the stomach for the father, and atherosclerosis in a sibling. 20

25 The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury, NJ) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with acid phenol pH 4.7, precipitated 30 using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water,

and DNase treated at 37°C. RNA extraction and precipitation was repeated as before. The mRNA was then isolated using the Qiagen Oligotex kit (QIAGEN, Inc.; Chatsworth, CA) and used to construct the cDNA library.

10 The mRNA was handled according to the recommended protocols in the SuperScript 5 Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013, Gibco/BRL). The cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105-01; Pharmacia), and those cDNAs exceeding 400 bp were ligated into pINCY 1. The plasmid pINCY 1 was subsequently transformed into DH5a™ competent cells (Cat. #18258-012; Gibco/BRL).

II Isolation and Sequencing of cDNA Clones

20 Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit (Catalog #26173; QIAGEN, Inc.). This kit enabled the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711, GIBCO/BRL™) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

25 The cDNAs were sequenced by the method of Sanger et al. (1975, J. Mol. Biol. 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems.

III Homology Searching of cDNA Clones and Their Deduced Proteins

30 After the reading frame was determined, the nucleotide sequences of the Sequence Listing or amino acid sequences deduced from them were used as query sequences against databases such as GenBank, SwissProt, BLOCKS, and Pima II. These databases which

contain previously identified and annotated sequences, were searched for regions of homology (similarity) using BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J.Mol.Evol. 36:290-300; Altschul, S.F. et al. (1990) J.Mol.Evol. 215:403-410).

5 BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms such as the one described in Smith et al. (1992, Protein Engineering 5:35-51), incorporated herein by reference, could have been used when dealing with primary sequence patterns and secondary structure gap penalties. The sequences disclosed in this application have lengths of at least 49 nucleotides, and no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

10

15 The BLAST approach, as detailed in Karlin et al. (supra) and incorporated herein by reference, searched for matches between a query sequence and a database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In this application, threshold was set at 10^{-25} for nucleotides and 10^{-14} for peptides.

PCT/US2002/014160

20 **IV Northern Analysis**

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

25 Analogous computer techniques using BLAST (Altschul (1993) supra, Altschul (1990) supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

30 The basis of the search is the product score which is defined as:

40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

| | | |
|----|---------|--|
| 5 | Step 1 | 94° C for 1 min (initial denaturation) |
| | Step 2 | 65° C for 1 min |
| | Step 3 | 68° C for 6 min |
| | Step 4 | 94° C for 15 sec |
| | Step 5 | 65° C for 1 min |
| | Step 6 | 68° C for 7 min |
| 10 | Step 7 | Repeat step 4-6 for 15 additional cycles |
| | Step 8 | 94° C for 15 sec |
| | Step 9 | 65° C for 1 min |
| | Step 10 | 68° C for 7:15 min |
| | Step 11 | Repeat step 8-10 for 12 cycles |
| 15 | Step 12 | 72° C for 8 min |
| | Step 13 | 4° C (and holding) |

A 5-10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQuick™ (QIAGEN Inc., Chatsworth, CA), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., *supra*). After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB)-agar (Sambrook et al., *supra*) containing 2x Carb. The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4

35 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers

used for the extension reaction were added to each well. Amplification was performed using the following conditions:

| | |
|--------|--|
| Step 1 | 94° C for 60 sec |
| Step 2 | 94° C for 20 sec |
| Step 3 | 55° C for 30 sec |
| Step 4 | 72° C for 90 sec |
| Step 5 | Repeat steps 2-4 for an additional 29 cycles |
| Step 6 | 72° C for 180 sec |
| Step 7 | 4° C (and holding) |

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NO:2 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

VI Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba 1, or Pvu II; DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x

saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

5 **VII Microarrays**

To produce oligonucleotides for a microarray, the nucleotide sequence described herein is examined using a computer algorithm which starts at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary 10 structure that would interfere with hybridization. The algorithm identifies 20 sequence-specific oligonucleotides of 20 nucleotides in length (20-mers). A matched set of oligonucleotides is created in which one nucleotide in the center of each sequence is altered. This process is repeated for each gene in the microarray, and double sets of twenty 20 mers are synthesized and arranged on the surface of the silicon chip using a light-directed chemical process (Chee, M. et al., PCT/WO95/11995, incorporated herein by reference).

In the alternative, a chemical coupling procedure and an ink jet device are used to synthesize oligomers on the surface of a substrate (Baldeschweiler, J.D. et al., PCT/WO95/25116, incorporated herein by reference). In another alternative, a "gridded" array analogous to a dot (or slot) blot is used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array may be produced by hand or using available materials and machines and contain grids of 8 dots, 24 dots, 96 dots, 384 dots, 1536 dots or 6144 dots. After hybridization, the microarray is washed to remove nonhybridized probes, and a scanner is used to determine the levels and patterns of fluorescence. The 20 scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the micro-array.

25 **VIII Complementary Polynucleotides**

Sequence complementary to the GSTS-encoding sequence, or any part thereof, is 30 used to decrease or inhibit expression of naturally occurring GSTS. Although use of

oligonucleotides comprising from about 15 to about 30 base-pairs is described, essentially the same procedure is used with smaller or larger sequence fragments. Appropriate oligonucleotides are designed using Oligo 4.06 software and the coding sequence of GSTS, SEQ ID NO:1. To inhibit transcription, a complementary oligonucleotide is designed from 5 the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GSTS-encoding transcript.

IX Expression of GSTS

10 Expression of GSTS is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector is also used to express GSTS in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues 15 is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

20 Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of GSTS into the bacterial growth media which can be used directly in the following assay for activity.

X Demonstration of GSTS Activity

25 GSTS activity is determined by measuring the enzyme catalyzed conjugation of GSH with 1-chloro-2,4-dinitrobenzene (CDNB), a common substrate for most GSTs. GST is incubated with 1 mM CDMB and 2.5 mM GSH together in 0.1 M potassium phosphate buffer, pH 6.5, at 25 °C. The conjugation reaction is measured by the change in absorbance at 340 nm using an ultraviolet spectrophotometer. Enzyme activity is proportional to the change in absorbance at 340 nm.

XI Production of GSTS Specific Antibodies

GSTS that is substantially purified using PAGE electrophoresis (Sambrook, *supra*), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using 5 DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (*supra*), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied 10 Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio iodinated, goat anti-rabbit IgG.

XII Purification of Naturally Occurring GSTS Using Specific Antibodies

Naturally occurring or recombinant GSTS is substantially purified by 20 immunoaffinity chromatography using antibodies specific for GSTS. An immunoaffinity column is constructed by covalently coupling GSTS antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GSTS is passed over the immunoaffinity column, and the column 25 is washed under conditions that allow the preferential absorbance of GSTS (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GSTS binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GSTS is collected.

XIII Identification of Molecules Which Interact with GSTS

GSTS or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GSTS, washed and any wells 5 with labeled GSTS complex are assayed. Data obtained using different concentrations of GSTS are used to calculate values for the number, affinity, and association of GSTS with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and 10 system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following 15 claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Hillman, Jennifer L.
Lal, Preeti
Corley, Neil C.
Shah, Purvi

(ii) TITLE OF THE INVENTION: NEW GLUTATHIONE-S-TRANSFERASE

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
(B) STREET: 3174 Porter Drive
(C) CITY: Palo Alto
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94304

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To Be Assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Billings, Lucy J.
(B) REGISTRATION NUMBER: 36,749
(C) REFERENCE/DOCKET NUMBER: PF-0430 US

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 650-855-0555
(B) TELEFAX: 650-845-4166
(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 226 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: BLADTUT04
(B) CLONE: 1554593

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Gly Pro Leu Pro Arg Thr Val Glu Leu Phe Tyr Asp Val Leu Ser
 1 5 10 15
 Pro Tyr Ser Trp Leu Gly Phe Glu Ile Leu Cys Arg Tyr Gln Asn Ile
 20 25 30
 Trp Asn Ile Asn Leu Gln Leu Arg Pro Ser Leu Ile Thr Gly Ile Met
 35 40 45
 Lys Asp Ser Gly Asn Lys Pro Pro Gly Leu Leu Pro Arg Lys Gly Leu
 50 55 60
 Tyr Met Ala Asn Asp Leu Lys Leu Arg His His Leu Gln Ile Pro
 65 70 75 80
 Ile His Phe Pro Lys Asp Phe Leu Ser Val Met Leu Glu Lys Gly Ser
 85 90 95
 Leu Ser Ala Met Arg Phe Leu Thr Ala Val Asn Leu Glu His Pro Glu
 100 105 110
 Met Leu Glu Lys Ala Ser Arg Glu Leu Trp Met Arg Val Trp Ser Arg
 115 120 125
 Asn Glu Asp Ile Thr Glu Pro Gln Ser Ile Leu Ala Ala Glu Lys
 130 135 140
 Ala Gly Met Ser Ala Glu Gln Ala Gln Gly Leu Leu Glu Lys Ile Ala
 145 150 155 160
 Thr Pro Lys Val Lys Asn Gln Leu Lys Glu Thr Thr Glu Ala Ala Cys
 165 170 175
 Arg Tyr Gly Ala Phe Gly Leu Pro Ile Thr Val Ala His Val Asp Gly
 180 185 190
 Gln Thr His Met Leu Phe Gly Ser Asp Arg Met Glu Leu Leu Ala His
 195 200 205
 Leu Leu Gly Glu Lys Trp Met Gly Pro Ile Pro Pro Ala Val Asn Ala
 210 215 220
 Arg Leu
 225

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1035 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: BLADTUT04
- (B) CLONE: 1554593

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

| | | | | | | |
|------------|------------|------------|-------------|------------|------------|-----|
| GGGCAGCTC | TGCCGGGTT | CGGGAAAAGG | AGCTCTGCT | GCCACTGCTC | TTCCGGAGCC | 60 |
| TGCAGCATGG | GGCCCTG | GCGCACCGTG | GAGCTCTTCT | ATGACGTGCT | GTCCCCCTAC | 120 |
| TCC | TGGCTGG | GCTTCGAGAT | CCTGTGCCGG | TATCAGAATA | TCTGGAACAT | 180 |
| TTGCGGCCCA | GCCTCATAAC | AGGGATCATG | AAAGACAGTG | GAAACAAGCC | TCCAGGTCTG | 240 |
| CTTCCCCGCA | AAGGACTATA | CATGGCAAAT | GACTAAAGC | TCCTGAGACA | CCATCTCCAG | 300 |
| ATTCCCATCC | ACTTCCCCAA | GGATTTCTTG | TCTGTGATGC | TTGAAAAGG | AAGTTTGTCT | 360 |
| GCCATGCGTT | TCCTCACCGC | CGTGAACCTG | GAGCATCCAG | AGATGCTGGA | GAAAGCGTCC | 420 |
| CGGGAGCTGT | GGATGCGCGT | CTGGTCAAGG | AATGAAGACA | TCACCGAGGC | GCAGAGCATC | 480 |
| CTGGCGGCTG | CAGAGAAGGC | TGGTATGTCT | GCAGAACAAAG | CCCAGGGACT | TCTGGAAAAG | 540 |
| ATCGAACGC | CAAAGGTGAA | GAACCAGCTC | AAGGAGACCA | CTGAGGCAGC | CTGCAGATA | 600 |
| GGAGCCTT | GGCTGCCCAT | CACCGTGGCC | CATGTGGATG | GCCAAACCCA | CATGTTATTT | 660 |
| GGCTCTGACC | GGATGGAGCT | GCTGGCGCAC | CTGCTGGGAG | AGAAGTGGAT | GGGCCCTATA | 720 |
| CCTCCAGCCG | TGAATGCCAG | ACTTTAAGAT | TGCCCGGAGG | AAGCAAAC | TTCGTATAAA | 780 |
| AAAAGCAGGC | CATCTGCTTA | ACCCTGGCT | CCACCATAAG | GCACTGGGAC | TCGGATTCT | 840 |

| | |
|---|------|
| CTATCTGATA GAGGTATTT CTGTGGCCCT GGGAGCTGTC TGTCTTCCC CTACCCCCAA | 900 |
| GGATGCCAGG AAGACGTCCA CCATTAGCCA TGTGGCAACC TTTACTTCTA TGCCTCACAA | 960 |
| GTGCCTTCA GAGAGCCCCA ATTCTGCTT CCCACAAAAT AAACCTAATG CCATCAGGCA | 1020 |
| AAACAAAAAA AAAAAA | 1035 |

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 226 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: ?

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

| | |
|---|--|
| Met Gly Pro Ala Pro Arg Val Leu Glu Leu Phe Tyr Asp Val Leu Ser | |
| 1 5 10 15 | |
| Pro Tyr Ser Trp Leu Gly Phe Glu Val Leu Cys Arg Tyr Gln His Leu | |
| 20 25 30 | |
| Trp Asn Ile Lys Leu Lys Leu Arg Pro Ala Leu Leu Ala Gly Ile Met | |
| 35 40 45 | |
| Lys Asp Ser Gly Asn Gln Pro Pro Ala Met Val Pro His Lys Gly Gln | |
| 50 55 60 | |
| Tyr Ile Leu Lys Glu Ile Pro Leu Leu Lys Gln Leu Phe Gln Val Pro | |
| 65 70 75 80 | |
| Met Ser Val Pro Lys Asp Phe Phe Gly Glu His Val Lys Lys Gly Thr | |
| 85 90 95 | |
| Val Asn Ala Met Arg Phe Leu Thr Ala Val Ser Met Glu Gln Pro Glu | |
| 100 105 110 | |
| Met Leu Glu Lys Val Ser Arg Glu Leu Trp Met Arg Ile Trp Ser Arg | |
| 115 120 125 | |
| Asp Glu Asp Ile Thr Glu Ser Gln Asn Ile Leu Ser Ala Ala Glu Lys | |
| 130 135 140 | |
| Ala Gly Met Ala Thr Ala Gln Ala Gln His Leu Leu Asn Lys Ile Ser | |
| 145 150 155 160 | |
| Thr Glu Leu Val Lys Ser Lys Leu Arg Glu Thr Thr Gly Ala Ala Cys | |
| 165 170 175 | |
| Lys Tyr Gly Ala Phe Gly Leu Pro Thr Thr Val Ala His Val Asp Gly | |
| 180 185 190 | |
| Lys Thr Tyr Met Leu Phe Gly Ser Asp Arg Met Glu Leu Leu Ala Tyr | |
| 195 200 205 | |
| Leu Leu Gly Glu Lys Trp Met Gly Pro Val Pro Pro Thr Leu Asn Ala | |
| 210 215 220 | |
| Arg Leu | |
| 225 | |

What is claimed is:

1. A substantially purified new glutathione S-transferase (GSTS) comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

5

2. A substantially purified variant of GSTS having at least 90% amino acid identity to the amino acid sequence of claim 1.

10 3. An isolated and purified polynucleotide sequence encoding the GSTS of
claim 1.

15 4. An isolated and purified polynucleotide variant having at least 90%
polynucleotide identity to the polynucleotide sequence of claim 3.

20 5. A composition comprising the polynucleotide sequence of claim 3.

6. An isolated and purified polynucleotide sequence which hybridizes under
stringent conditions to the polynucleotide sequence of claim 3.

25 7. An isolated and purified polynucleotide sequence which is complementary to
the polynucleotide sequence of claim 3.

8. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or
a fragment of SEQ ID NO:2.

25

9. An isolated and purified polynucleotide variant having at least 90%
polynucleotide identity to the polynucleotide sequence of claim 8.

30 10. An isolated and purified polynucleotide sequence which is complementary to
the polynucleotide sequence of claim 8.

11. An expression vector containing at least a fragment of the polynucleotide sequence of claim 3.

12. A host cell containing the expression vector of claim 11.

5

13. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, the method comprising the steps of:

- (a) culturing the host cell of claim 12 under conditions suitable for the expression of the polypeptide; and
- (b) recovering the polypeptide from the host cell culture.

10

14. A pharmaceutical composition comprising the GSTS of claim 1 in conjunction with a suitable pharmaceutical carrier.

15
20
25
30

15. A purified antibody which specifically binds to the GSTS of claim 1.

16. A purified agonist of the GSTS of claim 1.

17. A purified antagonist of the GSTS of claim 1.

18. A method for treating or preventing an immune response, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 15.

25

19. A method for treating or preventing a cancer, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 15.

30

20. A method for detecting a polynucleotide encoding GSTS in a biological sample containing nucleic acid material, the method comprising the steps of:

- (a) hybridizing the polynucleotide of claim 7 to the nucleic acid material of the biological sample, thereby forming a hybridization complex; and
- (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding GSTS in the biological sample.

21. The method of claim 20 wherein the nucleic acid material is amplified by the polymerase chain reaction prior to the hybridizing step.

ABSTRACT OF THE DISCLOSURE

5 The invention provides a human new glutathione S-transferase (GSTS) and polynucleotides which identify and encode GSTS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GS.

| | | | | | |
|---|-----|-----|-----|-----|-----|
| 9 | 18 | 27 | 36 | 45 | 54 |
| 5'-GGG CAG CCT CTG CCG GGT TCC GGG AAA AGG AGC TCC TGC CAC TGC TCT TCC | | | | | |
| 63 | 72 | 81 | 90 | 99 | 108 |
| GGA GCC TGC AGC ATG GGG CCC CTG CCG CGC ACC GTG GAG CTC TTC TAT GAC GTG | | | | | |
| M G P L P R T V E L F Y D V | | | | | |
| 117 | 126 | 135 | 144 | 153 | 162 |
| CTG TCC CCC TAC TCC TGG CTG GCC TTC GAG ATC CTG TGC CGG TAT CAG AAT ATC | | | | | |
| L S P Y S W L G F E I L C R Y Q N I | | | | | |
| 171 | 180 | 189 | 198 | 207 | 216 |
| TGG AAC ATC AAC CTG CAG TTG CGG CCC AGC CTC ATA ACA GGG ATC ATG AAA GAC | | | | | |
| W N I N L Q L R P S L I T G I M K D | | | | | |
| 225 | 234 | 243 | 252 | 261 | 270 |
| AGT GGA AAC AAG CCT CCA GGT CTG CTT CCC CGC AAA GGA CTA TAC ATG GCA AAT | | | | | |
| S G N K P P G L L P R K G L Y M A N | | | | | |
| 279 | 288 | 297 | 306 | 315 | 324 |
| GAC TTA AAG CTC CTG AGA CAC CAT CTC CAG ATT CCC ATC CAC TTC CCC AAG GAT | | | | | |
| D L K L R H H L Q I P I H F P K D | | | | | |
| 333 | 342 | 351 | 360 | 369 | 378 |
| TTC TTG TCT GTG ATG CTT GAA AAA GGA AGT TTG TCT GCC ATG CGT TTC CTC ACC | | | | | |
| F L S V M L E K G S L S A M R F L T | | | | | |

FIGURE 1A

故其子曰：「吾父之子，其名何也？」

FIGURE 1B

FIGURE 1C

| | | |
|-----|---|-----------|
| 1 | M G P L P R T V E L F Y D V L S P Y S W L G F E I L C R Y Q N I W N I N L Q L R | 1554593 |
| 1 | M G P A P R V L E L F Y D V L S P Y S W L G F E V L C R Y Q H L W N I K L K L R | gi1911749 |
| 41 | P S L I T G I M K D S G N K P P G L L P R K G L Y M A N D L K L L R H H L Q I P | 1554593 |
| 41 | P A L L A G I M K D S G N Q P P A M V P H K G Q Y I L K E I P L L K Q L F Q V P | gi1911749 |
| 81 | I H F P K D F L S V M L E K G S L S A M R F L T A V N L E H P E M L E K A S R E | 1554593 |
| 81 | M S V P K D F F G E H V K K G T V N A M R F L T A V S M E Q P E M L E K V S R E | gi1911749 |
| 121 | I W M R V W S R N E D I T E P Q S I L A A E K A G M S A E Q A Q G L L E K I A | 1554593 |
| 121 | I W M R I W S R D E D I T E S Q N I L S A A E K A G M A T A Q A Q H L L N K I S | gi1911749 |
| 161 | T P K V K N Q L K E T T E A A C R Y G A F G L P I T V A H V D G Q T H M L F G S | 1554593 |
| 161 | T E L V K S K L R E T T G A A C K Y G A F G L P T T V A H V D G K T Y M L F G S | gi1911749 |
| 201 | D R M E L L A H L L G E K W M G P I P P A V N A R L | 1554593 |
| 201 | D R M E L L A Y L L G E K W M G P V P P T L N A R L | gi1911749 |

FIGURE 2




FIGURE 3A




FIGURE 3B

**DECLARATION AND POWER OF ATTORNEY FOR
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

NEW GLUTATHIONE S-TRANSFERASE

the specification of which:

/ is attached hereto.

/ X / was filed on November 25, 1997, as application Serial No. 08/978,174 and if this box contains an X /, was amended on _____.

/ was filed as Patent Cooperation Treaty international application No. _____ on _____, 19____, if this box contains an X /, was amended on under Patent Cooperation Treaty Article 19 on _____ 19____, and if this box contains an X /, was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Docket No.: PF-0430 US

| Country | Number | Filing Date | Priority Claimed |
|---------|--------|-------------|------------------|
| | | | / / Yes / / No |
| | | | / / Yes / / No |

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

| Application Serial No. | Filed | Status (Pending, Abandoned, Patented) |
|---------------------------|-------|--|
| | | |

I hereby appoint the following:

| | |
|------------------------------|--------------------------------|
| LUCY J. BILLINGS | Registration No. 36,749 |
| MICHAEL C. CERRONE | Registration No. 39,132 |
| SHEELA MOHAN-PETERSON | Registration No. 41,201 |
| COLETTE C. MUENZEN | Registration No. 39,784 |
| KAREN J. ZELLER | Registration No. 37,071 |

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

**LUCY J. BILLINGS, ESQ.
INCYTE PHARMACEUTICALS, INC.
3174 PORTER DRIVE, PALO ALTO, CA 94304**

TEL: 650-855-0555 FAX: 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


**Sole Inventor or
First Joint Inventor:**

Full name: **JENNIFER L. HILLMAN**
Signature: Jennifer Hillman
Date: March 6/98
Citizenship: United States of America
Residence: Mountain View, California
P.O. Address: 230 Monroe Drive, #12
Mountain View, CA 94040

Second Joint Inventor:

Full name: **PREETI LAL**
Signature: Preeti Lal
Date: March 6th, 1998
Citizenship: India
Residence: Santa Clara, California
P.O. Address: 2382 Lass Drive
Santa Clara, CA 95054

Third Joint Inventor:

Full name: **NEIL C. CORLEY**
Signature: 
Date: 3-6-98
Citizenship: United States of America
Residence: Mountain View, California
P.O. Address: 1240 Dale Avenue, #30
Mountain View, CA 94040

Fourth Joint Inventor:

Full name: **PURVI SHAH**
Signature: 
Date: 3/6/98
Citizenship: India
Residence: Sunnyvale, California
P.O. Address: 1608 Queen Charlotte Drive, #5
Sunnyvale, CA 94087

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, Box Issue Fee, D.C. 20231 on NOVEMBER 12, 1999.
 By: 
 Printed: Jeannie G. Labra

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: NEW GLUTATHIONE S-TRANSFERASE

Serial No.: 08/978,174 Filing Date: November 25, 1997

Examiner: Eyler, Y. Group Art Unit: 1642

Batch No.: W94

Assistant Commissioner for Patents

Box Issue Fee

Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),
 REVOCATION OF POWER OF ATTORNEY AND
 APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Pharmaceuticals, Inc., having a principal place of business located at 3174 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 9094, Frame 0979, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

| | |
|---------------------------|------------------------|
| Narinder S. Banait | Reg. No. 43,482 |
| Adam Warwick Bell | Reg. No. 43,490 |
| Lucy J. Billings | Reg. No. 36,749 |
| Michael C. Cerrone | Reg. No. 39,132 |
| Diana Hamlet-Cox | Reg. No. 33,302 |
| Colette C. Muenzen | Reg. No. 39,784 |
| Lynn E. Murry | Reg. No. 42,918 |

Danielle M. Pasqualone
Susan K. Sather
David G. Streeter

Reg. No. 43,847
Reg. No. 44,316
Reg. No. 43,168

Please direct all correspondence to:

Legal Department
Incyte Pharmaceuticals, Inc.
3174 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: David G. Streeter, Incyte Pharmaceuticals, Inc., Phone: (650) 855-0555, Fax: (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE PHARMACEUTICALS, INC.

Date: November 10. 1999

By: Lee Bendekgey
Lee Bendekgey
VP, General Counsel/Corporate Secretary